Clinical trials: Seizures, Epileptic
Drug Resistant Partial Onset Seizure
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
A follow-on, two-year open-label extension study of ganaxolone as add-on therapy in adult patients with drug-resistant partial-onset seizures
- Trial name
- NCT02519439
- Testing
- ganaxolone
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Marinus Pharmaceuticals
Reflexology, Epilepsy
Reflexology on Seizure Frequency, Fatigue, Stress and Sleep Quality in Epilepsy Patients
Epilepsy is among the diseases that cause loss of neurological abilities regardless of any trauma. Reflexology is one of the complementary therapies based on activating the body's self-healing power through special hand…
- Conditions
- Reflexology, Epilepsy, Fatigue, Stress
- Trial name
- NCT06120101
- Testing
- Reflexology Massage
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Ataturk University
Drug Resistant Epilepsy, Focal Seizure
Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007
This is a randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of iQ-007.
- Trial name
- NCT06899230
- Testing
- iQ-007
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- iQure Australia Pty Ltd
Epilepsy
Self-management Intervention for Reducing Epilepsy Burden Among Ugandans With Epilepsy.
The goal of this clinical trial is to assess the efficacy of self management intervention for reducing epilepsy burden among Ugandans with epilepsy (SMART- U) vs.
- Trial name
- SMART (NCT06139198)
- Testing
- Self-MAnagement intervention for Reducing The epilepsy burden among Ugandans
- Where
- Uganda
- Volunteers
- 190 people
- Sponsor
- Makerere University
Neonatal Seizure
What Are the Determinant Factors of Ceasing Anti-seizure Medication in Infants With Neonatal Seizures?
The investigators aimed to determine the factors for ceasing anti-seizure medication in infants who experienced seizures during the neonatal period.
- Trial name
- NCT06211192
- Testing
- retrospective data collection
- Where
- Turkey (Türkiye)
- Volunteers
- 158 people
- Sponsor
- Balikesir University
Altered Mental Status, Generalized Nonconvulsive Seizure Disorder
Putting Electroencephalography (EEG) in the Emergency Department
The aim of the proposed research is to compare the diagnostic accuracy of a portable wireless electroencephalography (EEG) device (Biosignal Micro-EEG) to standard EEG in identifying abnormal EEG patterns (mainly non-convulsive…
- Conditions
- Altered Mental Status, Generalized Nonconvulsive Seizure Disorder, Status-epilepticus
- Trial name
- NCT01355211
- Where
- United States
- Volunteers
- 261 people
- Sponsor
- Bio-Signal Group Corp.
Consciousness Disorder
A Clinical Decision Aid for Diagnosing Transient Loss of Consciousness
BACKGROUND: Transient loss of consciousness (TLOC) - defined as spontaneous disruption of consciousness not due to head trauma and with complete recovery - has a lifetime prevalence of 50%.
- Trial name
- NCT05367999
- Testing
- initial Paroxysmal Event Profile
- Where
- 2 sites in United Kingdom
- Volunteers
- 186 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Seizures
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to…
- Trial name
- RESTORE2 (NCT00235755)
- Testing
- Retigabine
- Where
- 70 sites in United States, Australia and 11 more
- Volunteers
- 539 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Partial
Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide
The purpose of the trial is to investigate whether changes in lipids and hormonal parameters can be observed in blood when Carbamazepine treatment is replaced with Lacosamide treatment, while Levetiracetam treatment remains…
- Trial name
- VICTOR (NCT01375374)
- Testing
- Lacosamide, Levetiracetam
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 11 people
- Sponsor
- UCB Pharma
Epilepsy, Seizure Disorder
Policy on Optimal Epilepsy Management
This study examines the use of an online social media platform (PatientsLikeMe) to assist Veterans with epilepsy. The hypothesis is that the online social media platform, PatientsLikeMe, will improve selected patient-reported…
- Trial name
- POEM (NCT01762215)
- Testing
- PatientsLikeMe.com
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Northern California Institute of Research and Education
Seizure Disorder Generalized Tonic Clonic
Comparing the Outcome of Buccal Midazolam and Intramuscular Midazolam in Children Presenting With Seizures.
The goal of this clinical trial(Quasi Experimental) is to compare efficacy of oral midazolam over intra-muscular Midazolam in children suffering from seizures.
- Trial name
- NCT07626255
- Testing
- Midazolam
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Pakistan Air Force (PAF) Hospital Islamabad
Highly Drug-resistant Focal Epilepsy
An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy.
- Trial name
- NCT02625090
- Testing
- UCB0942
- Where
- 15 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 42 people
- Sponsor
- UCB Biopharma SRL
Epilepsy, Motor Partial, Psychogenic Seizures
Detecting PNES With Single-channel sEMG
This is a prospective, comparative, multicenter study of subjects being admitted for standard of care therapy in Epilepsy Monitoring Units in the Veteran's Affair (VA) Medical Centers.
- Trial name
- NCT03313362
- Testing
- SPEAC System, video EEG
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Brain Sentinel
Epilepsy
Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097
This Phase 3 trial is an open-label extension study of the placebo-controlled, double-blind VRX-RET-E22-302 trial. Patients who have completed the VRX-RET-E22-302 trial and who meet inclusion and exclusion criteria will be…
- Trial name
- NCT00310388
- Testing
- Retigabine (INN), Ezogabine (USAN)
- Where
- 67 sites in Australia, Belgium and 10 more
- Volunteers
- 376 people
- Sponsor
- GlaxoSmithKline
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
The goal of this clinical trial is to find out whether two existing medications-anakinra and tocilizumab-can effectively treat a rare and life-threatening brain condition called NORSE (New-Onset Refractory Status Epilepticus).
- Conditions
- New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
- Trial name
- COMBAT-NORSE (NCT07281027)
- Testing
- Anakinra, Tocilizumab, Standard medical treatment
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 438 people
- Sponsor
- Yale University
Epilepsy; Paediatric Partial Onset Seizures
Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)
The purpose of this study is to compare the safety and efficacy of zonisamide with placebo.
- Trial name
- NCT00566254
- Testing
- Zonisamide
- Where
- 43 sites in Belgium, Estonia and 7 more
- Volunteers
- 207 people
- Sponsor
- Eisai Inc.
Epilepsy, Partial
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
- Trial name
- NCT00355082
- Testing
- lamotrigine, 300 mg/day, lamotrigine, 250 mg/day
- Where
- 103 sites in United States, Argentina and 6 more
- Volunteers
- 226 people
- Sponsor
- GlaxoSmithKline
Epileptic Seizures
Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy
Epilepsy is a common disease affecting 0.5 to 1% of the general population. Epilepsies refractory to drug treatment lead to increased morbidity, mortality and high costs for public health (representing 75% of the costs associated…
- Trial name
- EPISODIUM (NCT02304029)
- Testing
- MRI
- Where
- 4 sites in France
- Volunteers
- 78 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Epilepsy, SUDEP
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
Sudden unexpected death in epilepsy patients (SUDEP) is devastating outcome for some patients with epilepsy. It ranks second only to stroke among neurological diseases in years of potential life lost.
- Trial name
- NCT02929667
- Testing
- Fluoxetine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rup Kamal Sainju
Developmental and Epileptic Encephalopathies, Epileptic Spasms
Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies
Epileptic spasms (ES) are a predominantly infantile seizure type observed frequently in certain genetic disorders. Ketogenic diet (high ratio of fat to carbohydrate/protein) is an established non-medication treatment for…
- Conditions
- Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
- Trial name
- NCT06700811
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Heather Olson